MB231 cells with SUMO2 in red and DAPI (nuclei) in blue. courtesy of Jim D. Sutherland (CIC bioGUNE).

SumiQ Therapeutics was founded in January 2017 by UbiQ, a biotech company focused on the development and commercialization of research tools and small molecule drugs targeting the ubiquitin system and Mercachem, a privately owned leading European contract research organization offering innovative medicinal chemistry solutions. The joined teams from UbiQ and Mercachem combine expertise in SUMO biology, chemistry, medchem and pre-clinical drug development to deliver proof-of-concept for our innovative targeted antitumour therapy, based on the inhibition of protein SUMOylation